Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

RCT (n=628) found pembrolizumab prolonged overall survival(OS) v. chemotherapy as 2nd line therapy in patients with PD-L1 CPS ≥ 10, (median 9.3 v 6.7 months; HR 0.69; 95% CI, 0.52 to 0.93; p=0.0074; estimated 12-month OS rate 43 v 20%), with fewer treatment-related adverse events

Journal of Clinical Oncology